MiRNA for Treating Diseases and Conditions Associated with Neo-angiogenesis

A method for identification of a substance capable of preventing, treating, reverting and/or delaying neo-angiogenesis or a condition or disease associated with neo-angiogenesis in a subject, the method comprising the steps of:

• (a) providing a test cell population capable of expressing a miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent thereof, preferably the test population comprises bladder cells, more preferably the test cell population comprises mammalian cells, even more preferably human cells;
• (b) contacting or incubating the test cell population with the substance;
• (c) determining the expression level of said miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent thereof or the activity or steady state level of said miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent thereof in the test cell population contacted or incubated with the substance;
• (d) comparing the expression, activity or steady state level determined in (c) with the expression, activity or steady state level of said miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent in a test cell population that is not contacted with the substance;
• and,
• (e) identifying a substance that produces a difference in expression level, activity or steady state level of said miRNA-9, miRNA-574, miRNA-7, miRNA-190b and/or miRNA-142 molecule or equivalent, between the test cell population that is contacted with the substance and the test cell population that is not contacted with the substance.